<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03534661</url>
  </required_header>
  <id_info>
    <org_study_id>L-NMMA 13-6415</org_study_id>
    <nct_id>NCT03534661</nct_id>
  </id_info>
  <brief_title>L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release</brief_title>
  <acronym>LNMMA</acronym>
  <official_title>Role of a Nitric Oxide Synthase Inhibitor on GLP-2 Mediated Intestinal Lipoprotein Release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut is able to retain some fat for many hours after a fatty meal. The gut hormone&#xD;
      glucagon-like peptide-2 (GLP-2) is known to release these fat stores in the gut, but it is&#xD;
      not known how GLP-2 achieves this. One possibility is that GLP-2 increases blood flow in the&#xD;
      gut. NG-monomethyl-L-arginine (L-NMMA) is a substance that inhibits nitric oxide synthase (an&#xD;
      enzyme that helps make nitric oxide which increases blood flow). This protocol examines&#xD;
      whether blocking gut blood flow with L-NMMA is able to prevent GLP-2 from releasing gut lipid&#xD;
      stores. Healthy participants will be treated with a combination of Teduglutide (a resistant&#xD;
      form of GLP-2) and L-NMMA, and their respective controls. Blood lipid levels will be measured&#xD;
      following treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-blind, cross over, Phase 3b clinical study. The protocol aims to study 15&#xD;
      healthy, lean, non-diabetic males and females for three studies each, in random order,&#xD;
      approximately four weeks apart, as follows.&#xD;
&#xD;
      Study A (L-NMMA + Teduglutide study): Volunteers will receive high-fat nutritional drink and&#xD;
      seven hours later a subcutaneous injection of Teduglutide (0.05mg/kg of body weight, which is&#xD;
      the FDA-approved route and daily dose for the treatment of short bowel syndrome).Thirty&#xD;
      minutes prior to Teduglutide, the subject will receive an intravenous infusion of L-NMMA up&#xD;
      to a maximum amount of 10 mg/kg, to inhibit nitric oxide synthesis. Lipid and lipoprotein&#xD;
      levels will be measured at regular intervals for 3 hours following the injection of&#xD;
      Teduglutide. Mesenteric blood flow will be measured at regular intervals by ultrasonography&#xD;
      on some volunteers.&#xD;
&#xD;
      Study B (Teduglutide + normal saline): The design is identical to study A, except that,&#xD;
      instead of L-NMMA, normal saline of the same volume will be infused.&#xD;
&#xD;
      Study C (Placebo + L-NMMA): The design is identical to study A, except that, instead of&#xD;
      Teduglutide, a placebo will be injected subcutaneously.&#xD;
&#xD;
      Mesenteric Blood Flow measurement: Mesenteric blood flow will be measured at the bedside for&#xD;
      some of the volunteers by ultrasonography in each study (A, B, C) before, during and after&#xD;
      the administration of L-NMMA and Teduglutide. The first evaluation will begin 15 min before&#xD;
      the start of the L-NMMA infusion and periodically afterwards.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Actual">March 20, 2019</completion_date>
  <primary_completion_date type="Actual">March 20, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each participant receives 3 randomized treatments.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded for participants</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Lipid Levels</measure>
    <time_frame>10.5 hours</time_frame>
    <description>Lipid levels in plasma and lipoprotein fractions are measured following treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Flow</measure>
    <time_frame>3 hours</time_frame>
    <description>Mesenteric blood flow rates are measured with ultrasound following treatments</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Teduglutide + Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Teguglutide + (L-NMMA control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teduglutide + L-NMMA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tedulgutide + L-NMMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + L-NMMA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(Teduglutide control) + L-NMMA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide + Normal Saline</intervention_name>
    <description>Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion</description>
    <arm_group_label>Teduglutide + Normal Saline</arm_group_label>
    <other_name>L-NMMA control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide + L-NMMA</intervention_name>
    <description>Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion</description>
    <arm_group_label>Teduglutide + L-NMMA</arm_group_label>
    <other_name>active treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + L-NMMA</intervention_name>
    <description>Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion</description>
    <arm_group_label>Placebo + L-NMMA</arm_group_label>
    <other_name>Teduglutide control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, aged 18 to 60 years&#xD;
&#xD;
          -  Body mass index 20 kg/m2 to 30 kg/m2&#xD;
&#xD;
          -  Hemoglobin above 130g/L.&#xD;
&#xD;
          -  Normal glucose tolerance in response to a 75g, 2-hr oral glucose tolerance test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a history of hepatitis/hepatic disease that has been active within the&#xD;
             previous two years.&#xD;
&#xD;
          -  Any significant active (over the past 12 months) disease of the gastrointestinal,&#xD;
             pulmonary, neurological, renal (creatinine &gt; 1.5 mg/dL), genitourinary, hematological&#xD;
             systems, or has severe uncontrolled treated or untreated hypertension (sitting&#xD;
             diastolic blood pressure &gt; 100 or systolic &gt; 180) or proliferative retinopathy&#xD;
&#xD;
          -  History of diabetes or oral glucose tolerance indicative of diabetes or impaired&#xD;
             glucose tolerance.&#xD;
&#xD;
          -  Any history of a myocardial infarction or clinically significant, active,&#xD;
             cardiovascular history including a history of arrhythmia's or conduction delays on&#xD;
             electrocardiogram, unstable angina, or decompensated heart failure.&#xD;
&#xD;
          -  Any laboratory values: aspartate transaminase &gt; 2x upper limit of normal; alanine&#xD;
             aminotransferase &gt; 2x upper limit of normal; thyroid-stimulating hormone &gt; 6&#xD;
             miliunit/l&#xD;
&#xD;
          -  Current addiction to alcohol or substances of abuse as determined by the investigator.&#xD;
&#xD;
          -  Mental incapacity, unwillingness or language barrier precluding adequate understanding&#xD;
             or cooperation&#xD;
&#xD;
          -  Taking any prescription or non-prescription medications at the time of the study&#xD;
&#xD;
          -  Having donated blood three months prior to and three months post study procedures&#xD;
&#xD;
          -  A pregnancy test will be performed 1 to 3 days prior to each study in all female&#xD;
             research participants. Those who test positive for pregnancy will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tornto General Hospital, UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
    <mesh_term>omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

